Looks like some resistance up to 5.50.
But...gettin' to 5.00 would be nice.
We floated 150 million more shares at the ASM.
15 million for insider stock options, 135 million for something else.
I'm thinking the 135 million shares are for a minority partnership at an undisclosed price.
If they sell for 3.00, that's 405 million dollars, which would do wonders for our debt and ensure that we have enough money until sales get going.
135 million shares would be 22% of the company without surrendering our NDA to anyone again.
Personally, I would love to see us sell those 135 million shares to Teva for international rights plus a seat on our Board.
Gives us a cash cushion in the event of a big market melt-down.
With the increased authorized shares, we can take advantage of bargain prices on assets we can use, too.
Start an ad campaign immediately. Get the word out. No one knows about us.
We have the ability to be the next big thing. The iPad, iWatch, iPod of the diabetic world.
With the Dexcom CGM, we have the ability to work with the IWatch. Diabetes now has an app for your phone /watch.
Start the ads. Be the next big social phenomenon.
I've held this stock for longer than I care to acknowledge. I believed in Al and I believe in the superior kinetics of Afrezza. It's the kinetics that will win this war. Once patients learn how to titrate themselves they will see dramatic changes in their A1Cs. The accounts on Twitter bear that out. Less needlesticks will attract the patients. Better control will keep them.
The market is huge. 28 million diabetics in this country with 20 million more expected in the next 3-4 yrs.
If you were born in 1960, diabetes has increased 10x in your lifetime. From 0.9% to 9 % of the population.
We can be profitable just being a niche product. I figure we need 2000-3000 units sold per week to see a profit.
But, we have the potential to be much more than a niche product.
It's our culture. I call it the bread culture. If you went out to eat this weekend you probably went to a sports bar where they serve lots of beer, fries, and burgers with huge buns. Highly-glycemic foods that carry huge carb loads. Those carbs can't be managed with aging pancreases. That's why so many older Americans are overweight.
So....now, we're relaunching without SNY. Mike Castagna seems like the right guy to lead us. He's concentrating on the Endos. Tough sledding there. The Endos have been managing Novolog and Humalog for years and they're pretty good at it although the protocols are very tough to adhere to and many diabetics fail to maintain good A1Cs. The Endos have built good relations with the Novo and Lilly reps and you can be sure that we'll get serious bad raps from them once we start making headway into their market.
I think the push needs to come from the patients in the form of an aggressive ad campaign.
26 million people watch Sunday Night Football. Over 2 million of those will be diabetic.
If only 10% of those go to a doctor and ask about Afrezza, that's 200,000 doctors' conversations.
If only 10% of those walk away with scripts, that's 20,000 new patients.
Yeah...The Outsulin thing is pretty goofy.
I'm guessing that was for the pediatric population (???)
People sold a lot of positions today.
Expect buying in MNKD next week.
If money is held in non-margin accounts, those sellers today can re-enter positions on Wed.
Looks to me like once we clear 4.60, there's a gap to be filled to 6.50 that goes back to Sept. of last year.
Point and Figure chart has a target of 8.00, also.
I see higher prices from here.....unless the world explodes.....which could happen at any time.
Stay tuned !!!
He owns a good amount of shares. He has 1 million stock options at roughly 1.00 per.
He has an FDA-approved drug that cost 2 Billion to get approved.
Process is approved, production facility approved, NDA has been transferred back from SNY.
Sales force recruited. Training about to begin.
We're a niche company for needlephobes but, because of our superior kinetics, we have the opportunity to be a real game-changer.
It's the best opportunity of this man's professional life.
Good luck to him and we all hope he does well.